Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• DNA repair vulnerabilities are common in cancers.
• Germline alterations in DNA repair genes impact cancer risk, treatment response, and outcomes.
• Targeted therapies exploiting DNA repair defects have revolutionized cancer treatment.

Purpose of the Study:

• To highlight the therapeutic relevance of germline DNA repair aberrations.
• To identify patients eligible for precision treatments.
• To discuss emerging DNA repair regulatory mechanisms.

Main Methods:

• Review of FDA-approved therapies targeting DNA repair vulnerabilities.
• Analysis of clinical success of synthetic lethality (e.g., BRCA deficiency and PARP inhibition).
• Assessment of defective mismatch repair as a predictor for immune checkpoint blockade response.
• Leveraging advances in next-generation sequencing for genetic profiling and germline testing.

Main Results:

• Germline DNA repair aberrations are crucial for predicting treatment response.
• Synthetic lethality approaches (e.g., PARP inhibitors) show significant clinical success.
• Defective mismatch repair predicts durable responses to immune checkpoint blockade.
• Increased genetic profiling yields extensive data on DNA repair genes.

Conclusions:

• Germline DNA repair aberrations are key biomarkers for precision cancer therapy.
• Targeted therapies include PARP inhibitors, immune checkpoint blockade, chemotherapy, and radiation.
• Understanding DNA repair mechanisms is vital for developing novel cancer treatments.